American logistics expert reports from China video: Trump tariffs will be paid by American not China, ALL sanctions by US & EU have failed miserably. Wegovy, and why one fat American is worth more than 7 fat Chinese. 美國物流專家從中國視訊報道：川普關稅將由美國納稅人而不是中國支付，美國和歐盟的所有製裁都慘敗。 Wegovy，以及為什麼一個美國胖子比七個中國胖子值錢

https://youtu.be/W0MDe0VHbsE?si=KgWsh12hX11YoUBb
https://www.tiktok.com/t/ZP8LofXwG/
https://www.biospace.com/drug-delivery/novos-wegovy-launched-in-china-at-a-fraction-of-us-price
https://www.bloomberg.com/news/articles/2024-11-18/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-us
https://www.atlanticcouncil.org/blogs/econographics/the-us-is-relying-more-on-china-for-pharmaceuticals-and-vice-versa/
https://www.statnews.com/2024/11/14/merck-keytruda-lanova-medicines-pd1-vegf/
https://www.politico.com/newsletters/politico-pulse/2024/10/31/grappling-with-supply-chain-crunch-00186356

American officials are passing new regulations intended to drive Chinese companies out of our pharmaceutical supply chains. And drug companies seem to concur, as they say publicly that they, too, need to diversify away from China.

The reality is the opposite. US and European drugmakers make giant profits from the drugs that are manufactured in China, then licensed for sale in the American market. Their motivation is the enormous price difference, between what patients pay in the United States, compared to the rest of the world.

美國官員正在通過新法規，旨在將中國公司逐出我們的藥品供應鏈。 製藥公司似乎也同意這一點，因為他們公開表示，他們也需要在中國以外多元化。

現實卻恰恰相反。 美國和歐洲的製藥商從在中國生產、然後在美國市場銷售的藥品中獲得巨額利潤。 他們的動機是美國患者與世界其他地區患者支付的費用之間存在巨大的價格差異.